
Conference Call Anapvida 1Q20



Covid-19 Recent initiatives





1Q20 Highlights – Hapvida (including acquisitions)¹ Key Operating and Financial Highlights

(R\$ million)	1Q20	1Q19	Δ	4Q19	Δ
Net Revenue	2,078.8	1,257.0	65.4%	1,785.4	16.4%
Health beneficiaries (thousands)	3,564	2,368	50.5%	3,511	1.5%
Dental beneficiaries (thousands)	2,810	1,623	73.1%	2,817	-0.3%
MLR - ex-SUS (with IBNR) ³	57.9%	57.0%	0.9 p.p.	58.0%	-0.1 p.p.
MLR – Total ³	61.6%	57.8%	3.8 p.p.	61.8%	-0.2 p.p.
Administrative Expenses ³	10.1%	10.4%	-0.3 p.p.	10.6%	-0.4 p.p.
Selling Expenses ³	7.4%	9.4%	-2.0 p.p.	8.2%	-0.8 p.p.
EBITDA ³	467.8	300.5	55.7%	374.8	24.8%
EBITDA margin ³	22.5%	23.9%	-1.4 p.p.	21.0%	1.5 p.p.
Net income ³	164.6	205.4	-19.9%	210.6	-21.9%
ROE (% LTM) ²	29.4%	64.7%	-35.3 p.p.	42.4%	-13.0 p.p.


Figures for 4Q19 refer to November and December 2019 for GSF and December 2019 for America. For 1Q20. GSF. América and RN Saúde were fully incorporated. Calculated using net income for the last 12 months divided by average equity for the last 5 quarters. excluding IPO resources for 2018 and Follow on resources for 2019. Numbers considering the effect of IFRS16. khapvida 👷

Own service network

Permanent investment in own network expansion



	1Q20	1Q19
Hospitals Beds	39 2,754	26 1,823
Walk-in emergency units	42	20
Clinics	194	75
Diagnostic units	177	84




Beneficiaries Health portfolio





(In thousands)





Health beneficiaries - Hapvida (including acquisitions) (In thousands)


Health beneficiaries Corporate




5

Beneficiaries Dental portfolio

ehapvida



Corporate Individual





Dental beneficiaries - Individual (In thousands)

Hapvida (ex-acquisitions) GSF 6

Average monthly ticket Health portfolio

📌 hapvida







Average monthly ticket Dental portfolio

R\$ 16.77

R\$ **10.77**

📌 hapvida












(In R\$ million)

+12.9% Hapvida ex-acquisitions +65.4% Hapvida including acquisitions



Medical Costs and Medical Loss Ratio (MLR)



Composition of Total Medical Costs Hapvida (ex-acquisitions)					
(R\$ million)	1Q20	1Q19	1Q20 x 1Q19	4Q19	1Q20 x 4Q19
Medical Costs - Cash	(756.9)	(694.8)	8.9%	(760.6)	-0.5%
Depreciation and Amortization (IFRS)	(24.5)	(19.4)	26.3%	(23.4)	4.7%
Change in IBNR provision	(4.2)	(2.7)	52.9%	16.3	-125.6%
Change in SUS reimbursement provision	(69.8)	(9.4)	639.2%	(63.5)	9.8%
Medical Costs - Total	(855.4)	(726.4)	17.8%	(831.3)	2.3%
Cash MLR (ex-IBNR provision; ex-SUS;ex-D&A)	53.3%	55.3%	-2.0 p.p.	54.7%	-1.4 p.p.
MLR (ex-SUS)	55.4%	57.0%	-1.6 p.p.	55.2%	0.2 p.p.
MLR - Total	60.3%	57.8%	2.5p.p.	59.7%	0.6 p.p.

MLR and Medical Costs



Composition of Total Medical Costs

Acquired Companies*

(R\$ million)	1Q20	4Q20	1Q20 x 4Q19
Medical Costs - Cash	(403.8)	(252.8)	59.7%
Depreciation and Amortization (with IFRS16)	(8.7)	(5.2)	67.3%
Change in IBNR Provision	(5.9)	(9.4)	-37.3%
Change in SUS reimbursement provision	(5.9)	(5.5)	7.2%
Medical Costs - Total	(424.2)	(272.8)	55.5%
Cash MLR (ex-IBNR provision; ex-SUS;ex-D&A)	61.2%	64.1%	-2.9 p.p.
MLR (ex-SUS)	63.4%	67.8%	-4.4 p.p.
MLR - Total	64.3%	69.2%	-4.9 p.p.


* Figures for 4Q19 refer to November and December 2019 for GSF and December 2019 for America. For 1Q20, GSF, América and RN Saúde were fully incorporated.

MLR and Medical Costs

Composition of Total Medical Costs					
Hápvida including acquisitions					
(R\$ million)	1Q20	1Q19	1Q20 x 1Q19	4Q19	1Q20 x 4Q19
Medical Costs - Cash	(1,160.7)	(694.8)	67.0%	(1,013.3)	14.5%
Depreciation and Amortization (IFRS16)	(33.2)	(19.4)	70.9%	(28.6)	16.1%
Change in IBNR provision	(10.1)	(2.7)	269.3%	6.9	-245.8%
Change in SUS reimbursement provision	(75.7)	(9.4)	701.3%	(69.0)	9.6%
Medical Costs - Total	(1,279.6)	(726.4)	76.2%	(1,104.1)	15.9%
Cash - MLR (ex-IBNR provision; ex-SUS; ex-D&A)	55.8%	55.3%	0.5 p.p.	58.4%	-1.0 p.p.
MLR (ex-SUS)	57.9%	57.0%	0.9 p.p.	58.0%	-0.1 p.p.
MLR - Total	61.6%	57.8%	3.8 p.p.	61.8%	-0.2 p.p.

Total Medical Costs Composition x MLR - Hapvida including acquisitions

(R\$ million and %)



📌 hapvida

SUS Reimbursement



(R\$ million)	1Q20	1Q19
ABIs provision	36.4	1.0
Principal charged through GRUs	33.4	7.6
Interest, monetary restatement and fines	-	0.8
SUS reimbursement – Acquired companies	5.9	-
SUS reimbursement – Medical costs	75.7	9.4
Interest, monetary restatement and fines	27.1	-
SUS reimbursement – Financial results	27.1	-
SUS reimbursement – Total Hapvida	102.8	9.4

Selling and administrative expenses


Selling expenses Administrative expenses (In R\$ million and %NOR) (In R\$ million and %NOR) 10.1% 9.5% 11.2% 9.4% **10.4%** 10.1% 8.9% 10.1% 8.7% 10.0% 9.5% 9.6% 9.4% 10.6% 10.4% -10.0% 8.2% 9.9% 9.6% 7.4% 210.1 188.5 154.6 146.5 69.9 33.0 31.6 22.9 155.5 140.2 129.4 131.9 125.1 123.0 130.8 123.7 122.6 118.7 1Q19 2Q19 3Q19 4Q19 1Q20 1Q19 2Q19 3Q19 4Q19 1Q20 Acquired companies Acquired companies

enapvida

-


EBITDA and EBITDA margin






Net income and net margin





Cash generation and capex





Disclaimer



This material reflects management's expectations and may contain estimates related to future events. Any information. data. forecasts or future plans herein refer to estimates. and therefore can not be taken as concrete evidence or a promise to the market. Hapvida is not responsible for investment operations or decisions taken based on the information herein. These estimates are subject to change without prior notice.

This material has been prepared by Hapvida Participações e Investimentos S.A. ("Hapvida" or the "Company") in accordance with the highest national and international standards. and it includes certain forward-looking statements that are primarily based on Hapvida's current expectations and projections of future events and financial trends that currently affect or may affect the company's business. and therefore they are not guarantees of future performance. They are based on management's expectations and involve a number of risks and uncertainties that could lead the company's financial situation and operating results to differ materially from those expressed in Hapvida's forward-looking statements.

Hapvida assumes no obligation to publicly update or revise any forward-looking statements. This material is disclosed solely for informational purposes and should not be construed as a request or an offer to buy or sell any shares or related financial instruments. Accordingly, this presentation is not a recommendation of investment and should not be considered as such. It is not related to specific investment objectives, financial situation or particular needs of any recipient. Neither does it make a statement or provide a guarantee, either express or implied, related to the accuracy, completeness or reliability of the information herein. This presentation should not be regarded as a substitute to the recipients' judgment. Any opinion expressed herein is subject to change without prior notice and Hapvida does not assume the obligation to update or revise them.